AssetMark’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
Other funds holding BCRX
JHC
AssetMark's BCRX Position: Q3 2026 in Review
AssetMark held its BioCryst Pharmaceuticals (BCRX) position steady in Q3 2026 at 4,768 shares worth $39.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1970.
AssetMark first reported a position in BCRX in Q4 2021 and has held it in 18 quarters since. The position peaked at $47.7K in Q2 2026. 250 funds tracked by Wall St. Rank hold BCRX as of Q3 2026.
- AssetMark held 4,768 shares of BioCryst Pharmaceuticals worth $39.7K as of Q3 2026.
- AssetMark left its BioCryst Pharmaceuticals share count unchanged in Q3 2026.
- BioCryst Pharmaceuticals made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #1970 holding.
- AssetMark first reported a position in BioCryst Pharmaceuticals in Q4 2021 and has held it in 18 quarters since.
- AssetMark's BioCryst Pharmaceuticals position peaked at $47.7K in Q2 2026.
- 250 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.